Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer
Silvia Sabbioni, Paola Guerriero, Ram C. Shankaraiah, Laura Masatti et autres
2 citationsCell Death Discovery
Massimo Negrini
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
583Publications signalées
56601Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
MicroRNA in disease regulationCancer-related molecular mechanisms researchCircular RNAs in diseasesChronic Lymphocytic Leukemia ResearchRNA modifications and cancer
Publications récentes
TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches
Elisa Callegari, Angelo Michilli, Farzaneh Moshiri, Bruno De Siena et autres
1 citationBioTech
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients
Giuseppe Bronte, Aldo Carnevale, Antonella Ciancetta, Donato Michele Cosi et autres
0 citationsJournal of Thoracic Oncology
Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis
Cristina Cristofoletti, Giulia Salvatore, Cristian Bassi, Massimo Negrini et autres
1 citationFrontiers in Immunology
THU-098 miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment
Elisa Monti, Clara Vianello, Ilaria Leoni, Giuseppe Galvani et autres
0 citationsJournal of Hepatology
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma
Ilaria Leoni, Giuseppe Galvani, Elisa Monti, Clara Vianello et autres
3 citationsInternational Journal of Molecular Sciences
Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation
Tania Rossi, Martina Valgiusti, Maurizio Puccetti, Giacomo Miserocchi et autres
5 citationsCell Death and Disease
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma
Ilaria Leoni, Giuseppe Galvani, Elisa Monti, Clara Vianello et autres
2 citationsPreprints.org
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study
Ennio Nano, Francesco Reggiani, Adriana Amaro, Paola Monti et autres
1 citationNon-Coding RNA
Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy
Lucilla D’Abundo, Cristian Bassi, Elisa Callegari, Farzaneh Moshiri et autres
8 citationsScientific Reports
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
Ennio Nano, Francesco Reggiani, Adriana Amaro, Paola Monti et autres
3 citationsPreprints.org
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report
Donato Michele Cosi, Cristina Fragale, Chiara Magri, Aldo Carnevale et autres
3 citationsInternational Journal of Molecular Sciences
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.